Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neptune Technologies & Bioressources Inc. - NTB.V -- Ignore unavailable to you. Want to Upgrade?

To: Sultan who wrote (214)	3/19/2014 1:08:06 PM
From: The Ox	Respond to of 902

I spoke to the CFO a while ago and he said there would be a very good chance (not assured) that they would either list the company or extend the date on the warrants before they expired. I wasn't sure if I should post that publicly, so I didn't. He simply was going over the different options the company had to choose from, not trying to suggest one way or the other what they would do. Now that they've done this, I don't think it's wrong to post this note.

To: Sultan who wrote (214)	4/1/2014 11:26:43 AM
From: The Ox	Read Replies (2) \| Respond to of 902

finance.yahoo.com "Our belief that Neptune's patents can be invalidated was recently reinforced by the USPTO institution, on March 24, 2014, of an inter partes review of Neptune's U.S. Patent No. 8,278,351. The USPTO concluded that there is reasonable likelihood that the petitioner will prevail in demonstrating unpatentability of the claims at issue. In addition, since no progress has been achieved during mediation, we have decided that it is not in our best interest to continue our efforts to try to negotiate a final settlement agreement with Neptune," said Dr. Ariel Katz, President and Chief Executive Officer of Enzymotec. "We believe we have meritorious defenses to all Neptune's patent claims, and we intend to continue to vigorously contest the complaints and to further challenge Neptune's patents."